A Vaccine To protect against Cervical Cancer

Cancer of the cervix is identified in more than 15, 000 American women annually, and it eliminates nearly 5, 000 of them. Nearly all of those cancers are believed to derive from contamination by the sexually transmitted human papillomavirus. For this virus, cancer is a reproductive method: it reproduces a unique genetics by placing them into the dna of cervical cells and producing those cells to separate uncontrollably. But now pathologist Tzyy- Choou Wu and his colleagues at Johns Hopkins may have found a method to struggle the lethal disease. They have produced a vaccine that in mice both destroys cancerous cells and keeps fresh cancers from forming.

Camouflaging inside cervical cells, the papillomavirus typically escapes a full-fledged immune response. Wu’s vaccine is made to smoke it out. The vaccine consists of a key viral protein--the one that triggers cervical cells growing out of control, linked with another protein referred to as lamp-1 and placed into a safe vaccinia virus. When the vaccinia is shot into a mouse, it gets gobbled up by macrophages and other immune sentinels; inside these cells, lamp-1 next ferries the papillomavirus protein to an inner organelle, named a lysosome, in which the protein is busted into pieces and shipped to the cell surface for display. The display warns passing T cells that it is time to increase and fan out to damage any other cells which contain the viral protein.

Connecting the protein to lamp-1, says Wu, was the vital technique that allowed his vaccine to succeed. By notifying T cells, it unleashes the entire power of the immune system to attack and kill tumor cells. Wu inoculated 30 mice with the vaccine, waited a month, and then injected them with tumor cells just like those found in cervical cancer. 80 % of these mice continued to be totally free of tumors three months later; in contrast, unvaccinated mice all developed tumors within 3 weeks. Wu also examined the vaccine on mice that had formerly had tumor cells injected into them. They stayed tumor-free, whereas control mice developed tumors within two weeks.

Even though vaccine might possibly one day be given to healthy women as a precautionary measure, Wu thinks that it can prove best now in treating women who are left with cancerous cells after a cervical tumor has been surgically taken out. Surgeons lower what they could cut, he says. But for those tumor cells that are spreading out, there is no way the surgeon can treatment them. Wu says he hope to see clinical tests of the vaccine begin next year.